2.5000
24-2月-25 15:45:00
15 分の遅延
株式
-0.0500
-1.96%
本日の幅
2.4900 - 2.6200
ISIN
N/A
ソース
NASDAQ
Cassava Sciences Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Clinical Program in Alzheimer’s Disease
08 2 2021 07:30:00 提供 Nasdaq GlobeNewswire
Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study
02 2 2021 07:30:00 提供 Nasdaq GlobeNewswire
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
04 1 2021 07:30:00 提供 Nasdaq GlobeNewswire